scholarly journals Hypertension and type 2 diabetes: What family physicians can do to improve control of blood pressure - an observational study

2011 ◽  
Vol 12 (1) ◽  
Author(s):  
Wayne Putnam ◽  
Beverley Lawson ◽  
Farokh Buhariwalla ◽  
Mary Goodfellow ◽  
Rose Anne Goodine ◽  
...  
Diabetologia ◽  
2006 ◽  
Vol 49 (8) ◽  
pp. 1761-1769 ◽  
Author(s):  
I. M. Stratton ◽  
C. A. Cull ◽  
A. I. Adler ◽  
D. R. Matthews ◽  
H. A. W. Neil ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Enver Atalar ◽  
Fatih Eskin ◽  
Haci Bayram Tugtekin ◽  
Alpaslan Karabulut ◽  
Suleyman Kanyilmaz ◽  
...  

Maintaining regular blood pressure control usually requires multidrug regimens rather than monotherapy. The objective of this study was to describe the effectiveness and safety of an angiotensin-converting enzyme inhibitor and a nondihydropyridine calcium channel blocker in a single-tablet combination in patients with hypertension, a heart rate higher than 70 beats/min, and type 2 diabetes mellitus (T2DM). This study was conducted in Turkey as a prospective, noninterventional, observational study. At 22 clinical sites, the data of 200 patients with hypertension were used for efficacy analysis; however, 262 patients received at least one dose of trandolapril/verapamil fixed-dose combination at two dose strengths. Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, PR interval, glycated haemoglobin (HbA1c), and albumin/creatinine ratios were recorded during 8 weeks of treatment. With treatment, the mean (±SD) SBP that was recorded as 162.8 (±14.642) mm Hg at baseline was reduced to 131.7±11.1 mm Hg at week 8 (p<0.05). Similarly, the mean DBP was reduced from 93.76±9.16 mm Hg to 77.6±7.6 mm Hg (p<0.001). Following 8 weeks of treatment, SBP and DBP values were reduced below 140 mm Hg and 90 mm Hg in most patients (81.5%), respectively. The mean heart rate as evaluated using electrocardiography measurements was reduced to 78.25 beats/min at week 8 as compared with baseline during trandolapril/verapamil single-pill combination treatment (p<0.001). Treatment with trandolapril and verapamil was well tolerated over 8 weeks with no unexpected safety signals. In conclusion, the single-pill combination of trandolapril and verapamil was considered effective in reducing and controlling blood pressure in patients with hypertension and T2DM. There was a significant improvement in HbA1c and ACR levels in a smaller subgroup of the patient cohort. The trandolapril/verapamil combination was evaluated as being safe and well-tolerated following a treatment period of 8 weeks. This trial was registered with NCT02298556.


2010 ◽  
Vol 28 (10) ◽  
pp. 2026-2035 ◽  
Author(s):  
Jan Cederholm ◽  
Soffia Gudbjörnsdottir ◽  
Björn Eliasson ◽  
Björn Zethelius ◽  
Katarina Eeg-Olofsson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document